Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18590
Title: Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer.
Austin Authors: Johnstone, Cameron N ;Chand, Ashwini;Putoczki, Tracy L;Ernst, Matthias 
Affiliation: Cancer & Inflammation Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, LaTrobe University, Heidelberg, VIC 3084, Australia
Department of Medical Biology, Melbourne University, Parkville, Victoria, Australia
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Cancer Metastasis Laboratory, Cancer Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Issue Date: Oct-2015
metadata.dc.date: 2015-07-14
Publication information: Cytokine & growth factor reviews 2015; 26(5): 489-98
Abstract: Interleukin (IL)-11 is a member of the IL-6 family of cytokines that is defined by the shared use of the GP130 signal transducing receptor subunit. In addition of its long recognized activities as a hemopoietic growth factor, IL-11 has an emerging role in epithelial cancer biology. Through the activation of the GP130-Janus kinase signaling cascade and associated transcription factor STAT3, IL-11 can confer many of the tumor intrinsic 'hallmark' capabilities to neoplastic cells, if they express the ligand-specific IL-11Rα receptor subunit. Accordingly, IL-11 signaling has recently been identified as a rate-limiting step for the growth tumors arising from the mucosa of the gastrointestinal tract. However, there is less appreciation for a potential role of IL-11 to support breast cancer progression, apart from its well documented capacity to facilitate bone metastasis. Here we review evidence that IL-11 expression in breast cancer correlates with poor disease outcome and discuss some of the molecular mechanisms that are likely to underpin these observations. These include the capacity of IL-11 to stimulate survival and proliferation of cancer cells alongside angiogenesis of the primary tumor and of metastatic progenies at distant organs. We review current strategies to interfere with IL-11 signaling and advocate that inhibition of IL-11 signaling may represent an emerging therapeutic opportunity for numerous cancers.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18590
DOI: 10.1016/j.cytogfr.2015.07.015
ORCID: 0000-0002-6399-1177
PubMed URL: 26209885
Type: Journal Article
Subjects: Cancer
IL-11
IL-6
Interleukin
STAT3
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 9, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.